Drug Firms Fear PBM ‘Discrimination’ Over List Price Reductions, Azar Tells Hearing

 
• By Cathy Kelly
Alex Azar, Trump’s HHS secretary nominee, who spoke at the Senate HELP committee 11/29/17

More from Pricing Debate

More from Market Access